Rhabdomyosarcoma (RMS) accounts for up to 10% of childhood cancers and nearly half of pediatric soft tissue sarcomas. While multimodal therapies have improved outcomes for low- and intermediate-risk patients, high-risk or metastatic…
Thiostrepton suppresses rhabdomyosarcoma progression by targeting the PI3K–AKT pathway
